BioSpace News Archive

BridgeBio Pharma, Inc. and National Resilience, Inc. today announced a strategic collaboration to manufacture and advance BBP-812, an investigational adeno-associated virus (AAV) 9 gene therapy for Canavan disease, and BBP-631, an investigational AAV 5 gene therapy for congenital adrenal hyperplasia (CAH).

Lokavant , the clinical trial intelligence platform company, today announces an $8 million strategic investment from global business titan Mitsui & Co. Ltd. to expand its AI-optimized platform across the Asia-Pacific (APAC) region.

Dignitana announces that the Palmetto GBA Medicare Administrative Contractor has issued a Local Coverage Determination to provide coverage guidance for Scalp Cooling for the Prevention of Chemotherapy-Induced Alopecia.

Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that it will present two posters at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting, which is being held October 13-16, 2023 in Vancouver, BC, Canada.

Biodesix, Inc., a leading diagnostic solutions company with a focus in lung disease, announced that new data will be presented at the CHEST Annual Meeting 2023 in Honolulu, Hawaiʻi.

KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted five newly-hired employees inducement options to purchase an aggregate of 103,000 shares of KalVista common stock on October 2, 2023 as inducements material to each employee entering into employment with KalVista.

Eli Lilly and Company and POINT Biopharma Global, Inc. announced a definitive agreement for Lilly to acquire POINT, a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer.

Aclaris Therapeutics, Inc. today announced the completion of enrollment into ATI-1777-AD-202, its Phase 2b trial of its investigational topical “soft” Janus kinase (JAK) 1/3 inhibitor, ATI-1777, in patients with mild to severe atopic dermatitis.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Intellia Therapeutics, Inc. (NASDAQ:NTLA) today announced an expanded research collaboration to develop additional in vivo CRISPR-based gene editing therapies focused on neurological and muscular diseases.

InspireMD, Inc. announced senior leadership additions and changes intended to support the company’s commercial growth initiatives, including potential approval of the CGuard Prime stent platform in the U.S., development of new stent delivery systems, and growth in existing approved territories outside of the U.S.